Moleculin to Participate in the Virtual Investor Closing Bell Series
Rhea-AI Summary
Moleculin (NASDAQ: MBRX) announced that Walter Klemp, Chairman and CEO, will participate in the Virtual Investor Closing Bell Series on Tuesday, December 2, 2025 at 4:00 PM ET.
Mr. Klemp will provide a corporate overview and business outlook, followed by a live Q&A. A live video webcast will be available on the Events page under Investors at moleculin.com. A replay will be posted two hours after the live event and remain accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MBRX
In the Nov 26 session, MBRX declined 22.03%, reflecting a significant negative market reaction. Argus tracked a trough of -32.6% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Warrant exercise financing | Negative | -27.1% | Exercise of warrants for cash proceeds with issuance of new unregistered warrants. |
| Dec 09 | Clinical trial update | Positive | -8.6% | Reported progress and timelines in pivotal MIRACLE Phase 2B/3 AML trial. |
| Dec 08 | Research collaboration | Positive | +0.1% | New preclinical collaboration to study Annamycin in GBM mouse models. |
| Nov 26 | Investor event announcement | Neutral | -22.0% | Announcement of participation in Virtual Investor Closing Bell Series. |
| Nov 26 | Reverse stock split | Negative | -22.0% | 1-for-25 reverse stock split to consolidate outstanding common shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative price reactions around financing and structural actions, and even a selloff following positive clinical progress, suggesting a pattern of pressure around capital structure and dilution-related events.
Over recent months, Moleculin has combined clinical progress with significant capital structure changes. A 1-for-25 reverse stock split effective Dec 1, 2025 and participation in an investor event on Dec 2, 2025 coincided with sharp share declines. Subsequent news highlighted new collaborations for Annamycin and advancement of the MIRACLE trial’s first 45 subjects toward Q1 2026 milestones. However, an offering-related warrant exercise for about $6.5 million in gross proceeds again aligned with a steep drop, underscoring sensitivity to financing actions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET
HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in the Virtual Investor Closing Bell Series on Tuesday, December 2, 2025 at 4:00 PM ET.
As part of the event, Mr. Klemp will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Klemp will answer as many questions as possible in the time allowed.
A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
